Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]
暂无分享,去创建一个
M. Engelhard | G. Brittinger | D. Huhn | H. Gerhartz | P. Meusers | W. Siegert | W. Wilmanns | R. Musch | G. Schlimok | P. Mueller
[1] H. Gerhartz,et al. Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. , 1993, Leukemia research.
[2] L. Gordon,et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[3] J. Radford,et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.
[4] N. Nissen,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Fibbe,et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. , 1992, Blood.
[6] Charles L. Bennett,et al. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease , 1992, Annals of Internal Medicine.
[7] I. Fabian,et al. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. , 1991, Experimental hematology.
[8] M. Kris,et al. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .
[9] J. Armitage,et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.
[10] C. Tiley,et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial , 1990, The Lancet.
[11] F. Herrmann,et al. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. , 1990, Haematology and blood transfusion.
[12] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Haanen,et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W Koepcke,et al. Analyses of group sequential clinical trials. , 1989, Controlled clinical trials.
[15] B. Coiffier,et al. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. , 1989, Blood.
[16] S. Jagannath,et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.
[17] R. Widen,et al. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3. , 1989, Blood.
[18] A. Burgess,et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. , 1989, Annals of internal medicine.
[19] F. Herrmann,et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Socinski,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.
[21] D. Longo,et al. The role of chemotherapy in diffuse aggressive lymphomas. , 1988, Seminars in hematology.
[22] M. Green,et al. EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.
[23] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.
[24] R. Fisher,et al. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. , 1987, Seminars in hematology.
[25] D. Golde,et al. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. , 1986, Blood.
[26] J. Gabrilove,et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.
[27] D. Weisenburger,et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[29] R. Fisher,et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] S. Nagata,et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor , 1986, Nature.